EP2440246A4 - Régulation par egfr et par2 de la perméabilité intestinales - Google Patents

Régulation par egfr et par2 de la perméabilité intestinales

Info

Publication number
EP2440246A4
EP2440246A4 EP10786502.4A EP10786502A EP2440246A4 EP 2440246 A4 EP2440246 A4 EP 2440246A4 EP 10786502 A EP10786502 A EP 10786502A EP 2440246 A4 EP2440246 A4 EP 2440246A4
Authority
EP
European Patent Office
Prior art keywords
par2
egfr
regulation
intestinal permeability
intestinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP10786502.4A
Other languages
German (de)
English (en)
Other versions
EP2440246A2 (fr
Inventor
Alessio Fasano
Karen Lammers
Terez Shea-Donohue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland at Baltimore
Original Assignee
University of Maryland at Baltimore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland at Baltimore filed Critical University of Maryland at Baltimore
Publication of EP2440246A2 publication Critical patent/EP2440246A2/fr
Publication of EP2440246A4 publication Critical patent/EP2440246A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP10786502.4A 2009-06-10 2010-06-10 Régulation par egfr et par2 de la perméabilité intestinales Ceased EP2440246A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18566209P 2009-06-10 2009-06-10
PCT/US2010/001670 WO2010144140A2 (fr) 2009-06-10 2010-06-10 Régulation par egfr et par2 de la perméabilité intestinales

Publications (2)

Publication Number Publication Date
EP2440246A2 EP2440246A2 (fr) 2012-04-18
EP2440246A4 true EP2440246A4 (fr) 2013-08-28

Family

ID=43309408

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10786502.4A Ceased EP2440246A4 (fr) 2009-06-10 2010-06-10 Régulation par egfr et par2 de la perméabilité intestinales

Country Status (7)

Country Link
EP (1) EP2440246A4 (fr)
JP (1) JP2012529508A (fr)
KR (1) KR20120031496A (fr)
CN (2) CN102481362A (fr)
AU (1) AU2010259213A1 (fr)
CA (1) CA2765075A1 (fr)
WO (1) WO2010144140A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120107329A1 (en) * 2009-06-10 2012-05-03 University Of Maryland, Baltimore EGFR and PAR2 Regulation of Intestinal Permeability
EP4187246A4 (fr) 2020-07-22 2024-02-07 FUJIFILM Corporation Procédé d'aide au diagnostic d'une maladie intestinale inflammatoire

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060040883A1 (en) * 2004-05-14 2006-02-23 The Regents Of The University Of California Methods for treating cancer using anti-Wnt2 monoclonal antibodies and siRNA

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458925B1 (en) * 1998-08-03 2002-10-01 University Of Maryland, Baltimore Peptide antagonists of zonulin and methods for use of the same
AU2002211658A1 (en) * 2000-10-13 2002-04-22 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
US7611480B2 (en) * 2003-04-24 2009-11-03 Levy Mark M Gastrointestinal bioreactor
JP2008545951A (ja) * 2005-05-13 2008-12-18 ユニバーシティ オブ メリーランド， ボルチモア ゾヌリンを決定することによる、処置養生法の有効性を評価するための方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060040883A1 (en) * 2004-05-14 2006-02-23 The Regents Of The University Of California Methods for treating cancer using anti-Wnt2 monoclonal antibodies and siRNA

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"AGA Abstracts S1448-M1084", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, vol. 126, no. 4, 1 April 2004 (2004-04-01), pages A249 - A249, XP022471374, ISSN: 0016-5085, DOI: 10.1016/S0016-5085(04)80010-6 *
M C ARRIETA ET AL: "Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse", GUT, vol. 58, no. 1, 1 October 2008 (2008-10-01), pages 41 - 48, XP055071471, ISSN: 0017-5749, DOI: 10.1136/gut.2008.150888 *
PAPP M. ET AL: "Haptoglobin Polymorphism: A Novel Genetic Risk Factor for Celiac Disease Development and Its Clinical Manifestations", CLINICAL CHEMISTRY, vol. 54, no. 4, 1 April 2008 (2008-04-01), pages 697 - 704, XP055105643, ISSN: 0009-9147, DOI: 10.1373/clinchem.2007.098780 *
PAPP M. ET AL: "S1256 Haptoglobin Polymorphism: A Novel Genetic Risk Factor for Celiac Disease Development and Its Clinical Manifestations", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, vol. 134, no. 4, 1 April 2008 (2008-04-01), pages A-211 - A-212, XP023432775, ISSN: 0016-5085, [retrieved on 20080401], DOI: 10.1016/S0016-5085(08)60978-6 *
SAGIV E ET AL: "992 Unraveling Novel Mechanisms By Which the CD24 Oncogene Serves As a Target for Colorectal and Pancreatic Cancer Treatment, Via Down-Regulation By Monoclonal Antibodies or SIRNA", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, vol. 134, no. 4, 1 April 2008 (2008-04-01), pages A - 149, XP023432489, ISSN: 0016-5085, [retrieved on 20080401], DOI: 10.1016/S0016-5085(08)60692-7 *
SANDRO DRAGO ET AL: "Gliadin, zonulin and gut permeability: Effects on celiac and non-celiac intestinal mucosa and intestinal cell lines", SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol. 41, no. 4, 1 January 2006 (2006-01-01), pages 408 - 419, XP055105654, ISSN: 0036-5521, DOI: 10.1080/00365520500235334 *
SAPONE A ET AL: "Inhibition of the zonulin pathway blocks the progression from pre-clinical autoimmunity to type 1 diabetes in BB/Wor rats", DIGESTIVE AND LIVER DISEASE, W.B. SAUNDERS, GB, vol. 38, 1 April 2006 (2006-04-01), pages S87 - S87, XP025948595, ISSN: 1590-8658, [retrieved on 20060401], DOI: 10.1016/S1590-8658(06)80231-8 *
SAPONE A ET AL: "Serum zonulin and intestinal permeability before and after a gluten-containing meal in both type 1 diabetes and their relatives", DIGESTIVE AND LIVER DISEASE, W.B. SAUNDERS, GB, vol. 38, 1 April 2006 (2006-04-01), pages S75 - S75, XP025948561, ISSN: 1590-8658, [retrieved on 20060401], DOI: 10.1016/S1590-8658(06)80197-0 *
SMECUOL ET AL: "Permeability, zonulin production, and enteropathy in dermatitis herpetiformis", CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, AMERICAN GASTROENTEROLOGICAL ASSOCIATION, US, vol. 3, no. 4, 1 April 2005 (2005-04-01), pages 335 - 341, XP005120726, ISSN: 1542-3565, DOI: 10.1016/S1542-3565(04)00778-5 *

Also Published As

Publication number Publication date
CN104940927A (zh) 2015-09-30
CN102481362A (zh) 2012-05-30
KR20120031496A (ko) 2012-04-03
WO2010144140A2 (fr) 2010-12-16
CA2765075A1 (fr) 2010-12-16
AU2010259213A1 (en) 2012-01-19
WO2010144140A3 (fr) 2011-05-19
WO2010144140A4 (fr) 2011-07-14
WO2010144140A8 (fr) 2012-01-26
JP2012529508A (ja) 2012-11-22
EP2440246A2 (fr) 2012-04-18

Similar Documents

Publication Publication Date Title
HUS2100009I1 (hu) Halauxifen-metil és piroxszulam kombinációja
EG27167A (en) Microemulsifiers and methods of making and using same
EP2556799A4 (fr) Procédé de production de pinces de tissu, et pince de tissu
EP2279291A4 (fr) Coférons et leurs procédés de fabrication et d'utilisation
EP2424357A4 (fr) Traitement de la neurodégénérescence et de la neuroinflammation
EP2637502A4 (fr) Inhibiteurs d'egfr sélectifs d'un mutant et leurs utilisations
EP2485678A4 (fr) Coférons et procédés de fabrication et d'utilisation de ceux-ci
ZA201109034B (en) Aminopyrrolidinone derivatives and uses thereof
IL213974A0 (en) Isoxazole-isoxazole and isoxazole-isothiazole derivatives
IL236830A0 (en) Diazahomoredene derivatives and methods of using them
EP2561072A4 (fr) Nanozymes, procédés de production de nanozymes, et procédés d'utilisation de nanozymes
GB0915515D0 (en) Treatment of vasculoproliferative conditions
GB0908507D0 (en) Hyperbaric dessing and method
EP2456948A4 (fr) Segment de conduit câblé et son procédé de fabrication
EP2578153A4 (fr) Audiomètre et procédé associé
GB2486994B (en) Optically variable devices and method of manufacture
IL206491A0 (en) Treatment of produce
IL197655A0 (en) Emulsions and methods of their production
PL2264358T3 (pl) Oprawa oświetleniowa i taśma oświetleniowa
HK1178526A1 (en) Tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof 8--7-
EP2490541A4 (fr) Derives d'ethynylthiazole substitues en position 2 et leurs utilisations
PT2563806E (pt) Leucolectinas humanas e suas utilizações
EP2791360A4 (fr) Régulation par egfr et par2 de la perméabilité intestinale
GB201115521D0 (en) Colorant-polyesters and methods of producing colorant-polyesters
EP2637639A4 (fr) Cosmétique résistant au transfert et procédé de préparation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120106

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20130725

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 3/10 20060101ALI20130719BHEP

Ipc: A61K 39/395 20060101AFI20130719BHEP

Ipc: A61P 37/00 20060101ALI20130719BHEP

Ipc: A61K 31/7105 20060101ALI20130719BHEP

Ipc: A61P 1/04 20060101ALI20130719BHEP

17Q First examination report despatched

Effective date: 20140311

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20151002